Royalty Pharma
RPRX
$27.41
Share price
3.87%
Change (1 day)
-17.37%
Change (1 year)
Categories
Royalty Pharma (RPRX) - Cash on Hand
Cash on Hand as of March 2024 : $1.53 B
According to Royalty Pharma's latest financial reports the company has $1.53 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Royalty Pharma - Cash on Hand chart (from 2019 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $1.23 B | -49.18% |
| 2022-12-31 | $2.42 B | -13.39% |
| 2021-12-31 | $2.80 B | 5.82% |
| 2020-12-31 | $2.64 B | 233.97% |
| 2019-12-31 | $0.79 B | -66.76% |
| 2018-12-31 | $2.38 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | $6.65 B | 334.00% | 🇺🇸 USA |
 Eli Lilly LLY | $2.58 B | 68.77% | 🇺🇸 USA |
 ANI Pharmaceuticals ANIP | $0.23 B | -84.45% | 🇺🇸 USA |